



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 031 627 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

30.08.2000 Bulletin 2000/35

(21) Application number: 00102289.6

(22) Date of filing: 17.02.2000

(51) Int. Cl.⁷: C12N 15/53, C12N 9/02,
C12N 1/21, C12N 5/10,
C12P 23/00, C07K 16/40,
C12Q 1/68, G01N 33/573
// (C12N1/21, C12R1:19)

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: 22.02.1999 EP 99103382

(71) Applicant:

F. HOFFMANN-LA ROCHE AG
4070 Basel (CH)

(72) Inventors:

- Bachmann, Heinrich
4451 Wintersingen (CH)
- Brugger, Roland
79106 Freiburg (DE)
- Friedlein, Arno Martin
79189 Bad Krozingen (DE)

- Wirtz, Gabriele Margarethe
42349 Wuppertal (DE)
- Woggon, Wolf-Dietrich
4102 Binningen (CH)
- Wyss, Adrian
4313 Möhlin (CH)
- Wyss, Markus
4419 Liestal (CH)

(74) Representative:

Keller, Günter, Dr. et al
Lederer, Keller & Riederer
Patentanwälte
Prinzregentenstrasse 16
80538 München (DE)

Remarks:

The applicant has subsequently filed a sequence
listing and declared, that it includes no new matter.

(54) **Beta-carotene 15,15'-dioxygenase**

(57) Nucleic acid sequences coding for a protein
having β,β -carotene 15,15'-dioxygenase activity and
their uses in diagnostics, the synthesis of vitamin A and
methods for the introduction of the β,β -carotene 15,15'-
dioxygenase cDNA into host cells are disclosed.


EP 1 031 627 A1

Description

[0001] The present invention concerns the cloning of β,β -carotene 15,15'-dioxygenase (EC 1.13.11.21), the enzyme responsible for the cleavage of β -carotene leading to vitamin A. The term vitamin A as defined in the present invention comprises a class of compounds including retinal, retinol, 3-dehydroretinol, retinoic acid, the isomers from these compounds as well as retinylesters. Proteins having β,β -carotene 15,15'-dioxygenase activity and nucleic acid sequences coding therefore can be used in different fields including but not limited to diagnostics, the technical production of vitamin A, the generation of transgenic plants in order to produce vitamin A in fruits and vegetables, or gene therapy.



[0002] Vitamin A is essential for man and animal and is largely formed in most organisms from its precursor carotenoids which, by themselves, can only be formed in plants, in photo-synthetic active and some other microorganisms. Man and most animals (in particular herbivores and omnivores) are able to convert such carotenoids, also called provitamins A, enzymatically into vitamin A. The most important enzyme for this process is the β,β -carotene 15,15'-dioxygenase (EC 1.13.11.21). The enzyme is located in the cytosol and forms retinal from β -carotene, as the principal substrate, in presence of oxygen according to scheme 1:

Scheme I:



[0003] The enzyme β,β -carotene 15,15'-dioxygenase is characterized by generating 2 mols retinal from 1 mol of β -carotene by central cleavage. But the enzyme is also able to convert a wide range of carotenoids into vitamin A-active compounds, as shown in scheme II:

Scheme II:



[0004] Highest known enzymatic activity is found in the intestine of herbivores, especially in duodenum. In other tissues like liver, lung, kidney and brain β,β -carotene 15,15'-dioxygenase is also detectable. Starting in 1955, many attempts have been undertaken to purify and characterize the enzyme by biochemical methods [Goodman (1965 and 1966), Fidge (1969), Laksmanan (1972), Sharma (1977) and Devery & Milborrow (British Journal of Nutrition (1994) 72, p. 397-414)]. However, none of these attempts has been successful. Specific activities of 600 pmol retinal formed/mg protein per hour have not been surpassed.

[0005] In the course of the present invention it was possible to purify the chicken enzyme to such a degree that a partial amino acid sequence could be obtained. The enzyme was enriched 226-fold, yielding a specific activity of 2500 pmol/h/mg. On a polyacrylamid gel of fractions from the final gel filtration run 15 bands were visible after Coomassie

blue staining. Two bands correlated with the enzymatic activity profile. With the first protein Edman sequencing and with the second MS spectroscopy was performed. Tryptic ingel digestion and subsequent microbore RP-HPLC peptide mapping in combination with MALDI-TOF MS and automated Edman degradation of this latter protein revealed 2 peptides of 11 and 18 amino acids. From this sequence information degenerate PCR primers were designed and synthesized.

[0006] With a PCR protocol a 51 bp (base pair) fragment was amplified within the longer peptide. From this sequence a homologous primer was synthesized and used in a second RT-PCR (reverse transcriptase - PCR) to amplify a 597 bp fragment.

[0007] This cDNA fragment was radioactively labeled and used for the screening of two positive pools from a chicken expression library in order to isolate the full length cDNA coding for β,β -carotene 15,15'-dioxygenase.

[0008] The positive pools were obtained from a cDNA library from chicken duodenum which was screened for β,β -carotene 15,15'-dioxygenase activity in a cellular transactivation assay. By this strategy several positive cDNA pools were identified. By combining the two strategies the gene coding for β,β -carotene 15,15'-dioxygenase could be successfully cloned. It is an object of the present invention to provide a protein having the vitamin A producing activity of β,β -carotene 15,15'-dioxygenase comprising an amino acid sequence which is identical or homologous to sequence ID no. 1 (shown in Fig. 4) whereby the degree of homology to sequence ID no. 1 is at least 60%.

[0009] After having provided the sequence of β,β -carotene 15,15'-dioxygenase isolated from chicken corresponding proteins from different animals like swine, cow, goat, dog, rabbit, poultry, fish and humans can easily be obtained. Since the sequence is known suitable regions of the nucleic acid sequence can be selected as primers for a polymerase chain reaction with a suitable nucleic acid which allows an easy and rapid amplification of the gene coding for the protein.

[0010] The present invention comprises therefore not only proteins having an amino acid sequence identical to the sequence given in sequence ID no. 1 but also such proteins which have an amino acid sequence homologous to the sequence ID no. 1. The degree of homology is, however, at least 60%, preferably 70%, more preferably 80% and especially preferred at least 90%. Homology as defined in the present invention means that when the amino acid sequences of two proteins are aligned at least the given percentage is identical. The alignment of the amino acids can be performed with the help of a suitable computer programme which is commercially available, preferably the Wisconsin Sequence Analysis Package GCG (Genetics Computer Group, University Research Park, Madison), Version 9.1, 1997. The remainder of the amino acids may be different. A homology of 90% for example means that 90% of the amino acids of the protein are identical compared with the amino acid sequence given in sequence ID no. 1 whereas 10% of the amino acids may be different. The proteins of the present invention have, however, the biological activity of β,β -carotene

[0011] 15,15'-dioxygenase which is explained above in more detail. Preferred proteins which are within the scope of the present invention are derived from other mammals or from humans.

[0012] Another aspect of the present invention concerns nucleic acid sequences coding for a protein having the biological activity of β,β -carotene 15,15'-dioxygenase. A nucleic acid sequence coding for the enzyme derived from chicken is shown in sequence ID no. 2 (see Figure 3). The nucleic acid sequences of the present invention code for a protein of the present invention or a part thereof. Shorter nucleotide sequences suitable for PCR have a length of at least 20 bases, preferably 25 bases and most preferred at least 30 bases.

[0013] The nucleic acid sequences of the present invention can be preferably used as primers for the specific amplification of a gene or part thereof coding for β,β -carotene 15,15'-dioxygenase. Primers can also be used for the specific amplification of 5' nontranslating or 3' nontranslating sequences of the cDNA described above. The nucleic acid sequences of β,β -carotene 15,15'-dioxygenase cDNA can be used as a probe for the detection of the coding as well as for the noncoding regions or parts thereof. The nucleic acid sequences of the present invention can be preferably used as antisense RNA probe for in situ hybridization.

[0014] It is especially preferred to use primers and probes having a part of the sequence given in sequence ID no. 2 as primers and/or probes in testkits which can be used for the amplification and/or detection of genes/mRNAs coding for β,β -carotene 15,15'-dioxygenase by polymerase chain reaction (PCR). The selection of suitable parts of the nucleic acid sequence can be performed by the person skilled in the art without difficulties. A nucleic acid sequence used as primer or probe is usually selected from a region which is highly conserved within the protein. Conserved means that the nucleic acid sequences of such regions of proteins obtained from different species are very similar. On the other hand the preferred nucleic acid sequence should not be present in other nucleic acid sequences which do not code for β,β -carotene 15,15'-dioxygenase, because this might lead to false positive results. By aligning several sequences derived from different species such regions can easily be determined. Although the nucleic acid can be a ribonucleic acid it is more preferred to have desoxyribonucleic acid sequences.

[0015] One preferred use in diagnostics is the determination of the β,β -carotene 15,15'-dioxygenase in patients. There is a variability in β -carotene cleavage potential among the population. Humans with low dioxygenase levels (with e.g. mutations or polymorphisms in the gene for β,β -carotene 15,15'-dioxygenase) could be identified and selected for vitamin A supplementation.

[0016] A diagnostic kit based on PCR can be designed to detect frequent mutations in the dioxygenase gene.

Another diagnostic option is quantification of mRNA by RT-PCR. With this diagnostic tool differences in expression of β , β -carotene 15,15'-dioxygenase in various tissues and in different species can be found.

[0017] Since the protein has been expressed and a method for purifying the protein is described in detail in the examples the person skilled in the art can use the protein or peptides derived from the amino acid sequences in order to generate antibodies which do specifically react with the protein. It is either possible to produce polyclonal antibodies by immunizing laboratory animals, like rabbits, sheeps or goats preferably with an adjuvant or monoclonal antibodies by the well-known technique described by Köhler and Milstein [European Journal of Immunology, 1976, 6 (7), p. 511-519]. The antibodies should specifically react with β , β -carotene 15,15'-dioxygenase in order to avoid an unspecific crossreaction. This means that the antibodies of the present invention should preferably react with an epitope which is present only on a protein of the present invention.

[0018] Such antibodies can be preferably used in immunoassays for the detection and/or quantification of β , β -carotene 15,15'-dioxygenase in a test fluid. The test fluid may be a liquid, like serum, obtained from a patient. There are several types of immunoassays which are well-known to the person skilled in the art. Very frequently one antibody, preferably a monoclonal antibody is fixed to a solid phase. This antibody is then brought into contact with the fluid containing the β , β -carotene 15,15'-dioxygenase and after washing it is further reacted with a second monoclonal antibody which binds to another epitope of the enzyme. The second antibody is usually labeled and shows the presence of the sandwich consisting of the antigen and two different antibodies.

[0019] The antibodies can also be used in laboratory methods like Western blots or immuno-precipitations. Preferably such antibodies can be used in immunohistochemistry to detect epitopes of β , β -carotene 15,15'-dioxygenase in embedded or fixed tissues or cells of any species of interest.

[0020] In a further embodiment of the present invention the β , β -carotene 15,15'-dioxygenase is used for the production of vitamin A whereby the enzyme cleaves enzymatically β -carotene into two molecules of retinal which will subsequently be reduced by retinol dehydrogenase to vitamin A. The β , β -carotene 15,15'-dioxygenase can be used to enzymatically convert β -carotene which may be obtained from plant sources. A preferred source of β -carotene is the alga *Dunaliella bardawil* which has a high endogenous level of β -carotene. Suitable algae can be grown conveniently and β -carotene can be purified therefrom at rather low cost. The carotene can be conveniently cleaved enzymatically by using a protein of the present invention. The carotene dioxygenase can preferably be immobilized in order to provide a continuous process.

[0021] Another aspect of the present invention concerns the introduction of the gene coding for a protein having β , β -carotene 15,15'-dioxygenase activity into a suitable host cell.

[0022] The first step in such a method is usually to insert the cDNA into a suitable vector. The vector must fit with the host cell into which the gene should be introduced. There are specific vectors available for bacteria, yeasts, plant cells, insect cells or mammalian cells. Preferably the gene is combined with genetic structures which provide the required genetic regulation like promoters, enhancers, ribosomal binding sites etc.

[0023] Systems for the expression of genes encoding carotenoid biosynthetic enzymes in procaryotes, especially in *E. coli* or *Bacillus subtilis* or *Flavobacter* and eucaryotes, e.g. fungi are known in the art and described e.g. in European Patent Application Publication No. (EP) 747 483 or in EP 872 554.

[0024] The vector having the gene and the other required genetic structures is then introduced into suitable host cells by well-known methods like transformation, transfection, electroporation or microprojectile bombardment.

Depending on the host cell it may be preferred to stably integrate the gene coding for a protein of the present invention into the genome of the host cell. The cells obtained by such methods can then be further propagated and if the cell is a plant cell it is possible to generate therefrom transgenic plants. In one embodiment of the present invention host cells are plant cells and tomato cells are especially preferred. The technology to produce transgenic tomatoes is well-established and the tomato contains sufficient β -carotene in order to come up with a reasonable vitamin A level after introduction of carotene dioxygenase into the tomato plant. In green pepper, melon or especially carrot the endogenous level of β -carotene is even higher and therefore also these plants are especially preferred.

[0025] Another preferred embodiment of the present invention concerns algae. Halotolerant algae may contain high levels of β -carotene. A transfection of such algae with an expression vector comprising the β , β -carotene 15,15'-dioxygenase cDNA leads to a high intracellular vitamin A level which can easily be recovered from such algae by simple purification steps.

[0026] In another aspect of the present invention a gene coding for a protein of the present invention can be introduced into mammalian cells and especially into human cells. It is for example possible to insert the gene coding for a β , β -carotene 15,15'-dioxygenase into suitable cells, for example peripheral blood stem cells. Such cells which contain the gene for β , β -carotene 15,15'-dioxygenase may be administered to people having mutations or deletions in the β , β -carotene 15,15'-dioxygenase gene. Such mutations and deletions, respectively, may have the effect that such patients are not able to cleave β -carotene enzymatically. Therefore, such patients always have a low vitamin A level and thus suffer from various developmental and ophthalmological problems. The administration of suitably transfected cells expressing the β , β -carotene 15,15'-dioxygenase to such patients by way of somatic gene therapy is a promising way to

improve their situation.

[0027] Some of the most important results of the present invention are summarized in the Figures.

[0028] Figure 1 shows the result from the last step of purification of β,β -carotene 15,15'-dioxygenase from the small intestine of chicken. The SDS-PAGE pattern and β,β -carotene 15,15'-dioxygenase activity of individual fractions from the gel permeation chromatography run are shown. On the gel, the protein A is marked by an arrow and seemed to correlate best with the β,β -carotene 15,15'-dioxygenase activity. It was therefore chosen for further amino acid sequence analysis. The abbreviations have the following meaning: Std.: molecular weight standard; conc.: concentrate loaded onto the gel permeation chromatography column.

[0029] Figure 2 shows schematically the transactivation assay in eukaryotic cells. cDNAs are transfected and expressed in MCF-7 cells. When incubated with β -carotene, a positive pool shows cleavage activity. The cleavage product retinal is further oxidized to retinoic acid (RA) which binds to the endogenous receptor. The receptor/ligand complex binds to the response element on the reporter plasmid and leads to an enhanced transcription of the luciferase gene. The luminescence signals are detected in a luciferase assay with a sensitive CCD camera.

[0030] Figure 3 shows the cDNA sequence (sequence ID no. 2) for β,β -carotene 15,15'-dioxygenase which has a length of 3090 base pairs excluding the poly A tail. 132 base pairs are 5' nontranslating sequence, the coding sequence has 1578 base pairs and the 3' nontranslating sequence 1380 base pairs, respectively. A putative poly A signal is found at position 3073.

[0031] Figure 4 shows the derived amino acid sequence (sequence ID No. 1) of β,β -carotene 15,15'-dioxygenase derived from chicken having 526 residues. The amino acid sequence is given in the one letter code.

[0032] Figure 5 shows a comparison of the β,β -carotene 15,15'-dioxygenase amino acid sequence with a protein having the designation RPE65 which was found by a sequence comparison in EMBL Genbank as the protein having the highest homology to the β,β -carotene 15,15'-dioxygenase of the present invention.

[0033] Figure 6 shows two fractions of β,β -carotene 15,15'-dioxygenase eluted from a Co^{2+} -chelate column. In lanes 1 and 2 two different fractions were loaded and lane 3 is a low range molecular weight marker.

[0034] Figure 7 shows an HPLC analysis of an activity test of β,β -carotene 15,15'-dioxygenase which was cloned and expressed in *E. coli*.

[0035] Figure 8 is a proof that the peak representing the only product of the enzymatic cleaving is retinal.

[0036] The present invention is further illustrated in the following examples:

Example 1:

Assay of β,β -carotene 15,15'-dioxygenase activity

[0037] For the tests the following solutions were prepared:

- Solution 1 (mixed micelle solution): Glycocholic acid (1.16 g) was dissolved in 5 ml H_2O under stirring and by drop-wise addition of 5 N NaOH. After pH was adjusted to 6.8-7.2 with acetic acid and the volume increased to 10 ml with H_2O , 80 mg of asolectin (Fluka) were added and dissolved under stirring.
- Solution 2 (substrate solution): 500 μl of an α -tocopherol solution (10 mg/ml in hexane) and 235 μg of a β -carotene solution (80 $\mu\text{g}/\text{ml}$ of pure all-E- β -carotene in benzene) were mixed in a glass vial, protected from light and the solvents evaporated under a gentle nitrogen stream. 1 ml of solution 1 was added under vortexing and eventually a few short ultrasonic bursts until a clear solution occurred.
- Solution 3 (homogenization buffer): 100 mM KH_2PO_4 adjusted with 5 N KOH to pH 7.8 and containing 4 mM MgCl_2 , 6 H_2O and 30 mM nicotinamide.
- Solution 4 (GSH solution): 60 mg/ml reduced glutathione dissolved in solution 3.
- Solution 5 (standard solution): 10 $\mu\text{g}/\text{ml}$ vitamin A acetate in hexane/chloroform 9:1.

[0038] Activity assay: 2 ml enzyme preparation (approx. 4 mg protein, assayed by BCA protein assay, Pierce Chemicals) were placed in a light-protected glass vial in a shaking water bath (30 min., 37 °C). 0.2 ml solution 4 was added and the reaction was started after 2 min. of temperature equilibration by addition of 50 μl solution 2. After 3 h, the reaction was stopped by placing the vials on ice and subsequent addition of 1 ml acetonitrile followed by 5 ml chloroform. The vials were vortexed 3 times for 7 s and phase separation was enforced by centrifugation for 5 min. at 5000 g. Extraction was repeated twice with 0.6 ml chloroform. The combined chloroform phases were evaporated and resolubilized in 200 μl solution 5 under short sonication. Insoluble material was removed by filtration through 0.45 μm filters. An aliquot of 20 μl was separated by HPLC on a reversed phase C_{18} column (Lichrospher 100, 5 μm , 12.5 cm x 4.6 mm, Bischoff Chromatography, Leonberg, Germany; 1 ml/min, column temperature 25°C) with a discontinuous, optimized gradient of acetonitrile/tetrahydrofuran/(1% ammonium acetate in H_2O) from 50:20:30 (eluent A) to 50:44:6 (eluent B). These conditions allow complete separation of β,β -carotene and retinal as well as apo- β -carotenals and retinoic

acids. Calibration curves were made for both β , β -carotene and retinal in the concentration ranges 2-40 and 1-10 ng/ μ l, respectively, and were correlated to the value of vitamin A acetate which served as an internal standard. Enzymatic activity was expressed as the amount of retinal liberated in the activity assay during 3 h of incubation at 37 °C (100% = 17.6 nmol).

Example 2:

Purification of β , β -carotene 15,15'-dioxygenase

[0039] Purification was done as rapidly as possible, and all buffers and equipments were cooled to 4 °C.

[0040] Solution 6 (protease inhibitor-containing homogenisation buffer): 125 mM benzamidine \cdot HCl, 250 mM 6-aminocaproic acid and 125 μ M soybean trypsin inhibitor were dissolved in H₂O by sonication. A 4 ml-aliquot of this solution was mixed with 100 ml of solution 3.

[0041] Solution 7: 10 mM KH₂PO₄, 1 mM reduced glutathione, pH 7.8.

[0042] Solution 8 (eluent A, phenyl-Sepharose chromatography): 10 mM KH₂PO₄, 1 mM reduced glutathione, 0.5 M (NH₄)₂SO₄, pH 7.8.

[0043] Solution 9 (eluent B, phenyl-Sepharose chromatography): 10 mM KH₂PO₄, 1 mM reduced glutathione, 10% glycerol, pH 7.8.

[0044] Solution 10 (eluent B, Poros HQ chromatography): 10 mM KH₂PO₄, 1 mM reduced glutathione, 0.5 M NaCl, 10% glycerol, pH 7.8.

[0045] Solution 11 (elution buffer for gel permeation chromatography): 50 mM KH₂PO₄, 1 mM reduced glutathione, 150 mM NaCl, 10% glycerol, pH 7.8.

[0046] Laying hens at age of 20-24 weeks (strain Lohmann LSL, Hatchery Wuethrich, CH-3123 Belp, Switzerland) were kept on a pigment-free chicken diet (Kliba 3179, Kliba, CH-4303 Kaiseraugst, Switzerland). The animals were killed by decapitation and the first 20 cm of the duodenal loop was removed, separated from pancreas and rinsed with 40 mL each of 0.9% NaCl solution. The intestines were immediately frozen in dry ice and stored at -80°C until use.

[0047] Ten intestines were thawed on ice in approx. 2 h and opened length-wise in an ice cooled Petri dish. The mucosa was scraped off with a slide, weighed and homogenized in a Teflon-glass Potter-Elvehjem homogeniser in 4 volumes of solution 6 with six strokes. Upon centrifugation at 62000 g for 1 h, the clear supernatant was divided into 32 aliquots of 15 ml each. From these preparations an ammonium sulphate fractionation was made. The precipitate obtained from the 20-45% step was centrifuged at 5000 g for 10 min. and the pellet was stored at -80°C for further use.

[0048] Ten aliquots of the (NH₄)₂SO₄ pellet were dissolved in 150 ml of solution 7, sterile-filtered and loaded on a HiLoad 26/10 phenyl-Sepharose High Performance column (column volume 53 ml; Pharmacia, Uppsala, Sweden) equilibrated with solution 8. Proteins were eluted at a flow rate of 8 ml/min with a steep gradient over 1 column volume (CV) from solution 8 to solution 9. β , β -Carotene 15,15'-dioxygenase eluted at a conductivity of < 1 mS/cm, but only fractions with a conductivity of < 1 mS/cm were pooled and directly loaded onto a 30 ml Blue Sepharose 6 Fast Flow column (Pharmacia) equilibrated with solution 9. β , β -Carotene 15,15'-dioxygenase activity eluted (at a flow rate of 8 ml/min) in the break-through fractions which were (again) directly loaded onto a 20 ml Poros HQ/M anion exchange chromatography column (PerSeptive Biosystems, Framingham, MA, USA) equilibrated with solution 9. β , β -Carotene 15,15'-dioxygenase was eluted at a flow rate of 15 ml/min with a linear gradient over 18 CV from solution 9 to solution 10. Activity was detected in the gradient in a conductivity range of 10-20 mS/cm. The pooled fractions (70 ml) were concentrated to ~1.3 ml with Ultrafree-15 filter units (MW cut-off 50,000; Millipore, Bedford, MA, USA). An aliquot of the concentrate (500 μ l) was loaded onto a Superdex 200 HR 10/30 gel filtration column (CV 24 ml; Pharmacia) and eluted at a flow rate of 0.5 ml/min with solution 11. Aliquots of each fraction were used for activity assays (see example 1) and, upon concentration, for SDS-PAGE (with MOPS running buffer) on 10% NuPAGE gels (Novex, San Diego, CA, USA). The results of this experiment are shown in Fig. 1 and Table 1.

Purification step	Total protein [mg]	Total activity [nmol/h]	Yield [%]	Specific activity [pmol/(h·mg)]	Purification factor
(NH ₄) ₂ SO ₄ pellet	779	8.61	100	11.0	—
phenyl-Sepharose Blue	80.8	8.27	96.1	102	9.27
Sepharose Blue	16.0	8.86	103	554	50.1
Poros HQ	1.56	3.90	45.3	2500	226

Table 1: Summary table for the purification of β,β -carotene 15,15'-dioxygenase starting with 10 aliquots of the (NH₄)₂SO₄ pellet (means of 3-4 measurements).

Example 3:

Amino acid sequence information for β,β -carotene 15,15'-dioxygenase

[0049] For amino acid sequence analysis, fractions of the gel filtration run (as shown in Fig. 1) were separated on a 8-16% Tris/glycine gel (Novex), and the proteins transferred to an Immobilon P^{SO} membrane (Millipore) and stained with amido black.

[0050] Since protein A proved to be N-terminally blocked, multiple aliquots of fraction 18 from the gel filtration run (see Fig. 1) were separated on a 10% Tris/glycine gel (Novex), and the gel was stained with Colloidal Coomassie Blue (Novex). The band corresponding to protein A was excised from the gel, and the protein digested in-gel with trypsin. The tryptic digest was separated by micro-bore reversed-phase HPLC on a 150 x 1.0 mm Vydac C₁₈ column (Vydac, Hesperia, CA, USA). Peptides were eluted with an acetonitrile gradient in 0.1% trifluoroacetic acid, and peptide containing fractions were collected for further analysis. Two fractions could be identified by MALDI-TOF-MS (Voyager Elite, PerSeptive Biosystems) to contain one single peptide each. N-terminal Edman degradation revealed the following sequences:

- (1) Ala-Glu-Val-Gln-Gly-Gln-Leu-Pro (Seq. ID No.3)
 (2) Asn-Lys-Glu-Glu-His-Pro-Glu-Pro-Ile-Lys-Ala-Glu-Val-Gln-Gly-Gln-Leu-Pro (Seq. ID No. 6)

[0051] Note that the last 8 amino acids of peptide (2) correspond to peptide (1).

Example 4:

Cloning the full length cDNA for the β,β -carotene 15,15'-dioxygenase

A) RNA isolation:

[0052] 4 week old Vedette chicken were killed, the duodenum was removed, washed with sterile PBS and cut open with scissors. The mucosal layer was scraped off with a glass slide, weighed and homogenized immediately with a Polytron in 1 ml of Trizole reagent (Life Technologies) per 100 mg of tissue. Then the standard protocol from Life Technologies was followed. Poly A mRNA was isolated by the polyAtract mRNA isolation kit from Promega Corporation, Madison.

B) PCR and RT-PCR:

[0053] In the peptide sequence NKEEHPEPIKAEVQGQLP (peptide 2 of Example 3) (Seq. ID No. 7) two degenerate primers were designed: In order to have a lower degeneracy the base Inosin was used in one and in two wobble positions, respectively.

5' primer: 5'AAC AAR GAR GAS CAY CCI GA 3' (Seq. ID No. 8) (20 mer with a degeneracy of 16x)

3' primer: 5'SAG CTG ICC CTG IAC YTC SGC 3' (Seq. ID No. 9) (21 mer with a degeneracy of 8x)

R= A or G, S= C or G, Y= C or T

[0054] The oligos were synthesized on a Pharmacia Gene Assembler Plus using standard phosphoramidite chemistry. Deprotection was done with 1 ml conc. ammonium hydroxide solution (Applied Biosystems) and final desalting was performed with a NAP 10 column (Amersham Pharmacia Biotech).

[0055] For PCR 100 ng chicken duodenal cDNA were taken as template and the following steps performed: 94°C 30"; 52°C 30"; 72°C 1' for 40 cycles. The resulting band of 51 bp was cut out from a 10% polyacrylamide gel, electrophoresed on DEAE paper at 300 V for 1.5 h, eluted from the DEAE paper once with 40 µl and twice with 30 µl 1.5 M NaCl, 5 mM Tris, 0.5 mM EDTA, precipitated with 2.5 volumes of ethanol 100% and 1 µg glycogen, washed with 0.5 ml of 80% ethanol, dried and dissolved in 20 µl TE (10 mM Tris, 1 mM EDTA).

[0056] The resulting fragment of 51 bp was cloned into pGEM-T Easy, a commercially available T/A cloning vector (Promega Corporation, Madison). The corresponding cDNA sequence was determined by automated fluorescent sequencing on a Vistra DNA Sequencer 725 (Amersham Pharmacia Biotech).

[0057] From the above DNA sequence a homologous forward primer was derived:

5' TCTGAATTCCGGAGCCCATAAAAGC 3' (primer diox12) [Seq. ID No. 10]

[0058] At the 5' end an EcoRI site (underlined sequence) was introduced; the following 17 nucleotides are homologous to the previously obtained dioxigenase sequence.

[0059] In a RT-PCR reaction a polyT/Not primer (commercially available from Invitrogen, San Diego) was used as reverse primer together with primer diox12.

[0060] One tube RT-PCR kit from Boehringer Mannheim was taken and the corresponding protocol followed:

mix 1:	
18.3 µl	H ₂ O
2.5 µl	DTT (100 mM)
1.0 µl	dNTPs (10 mM)
1.0 µl	oligo dT/Not (0.2 µg/µl) (3' primer)
1.0 µl	diox12 (5' primer) (20 µM)
0.2 µl	RNAse inhibitor (40 U/µl)
1.0 µl	chicken duodenal total RNA (2.2 µg/µl)
25.0 µl	
mix 2:	
14.0 µl	H ₂ O
10.0 µl	RT-PCR buffer 5x
1.0 µl	enzyme mix (AMV RT, Taq and Pwo DNA Polymerase)
25.0 µl	

[0061] The 2 mixes were combined and the PCR protocol started on a MJ Research PTC200 DNA Engine.

50°C	30'	10 cycles
94°C	2'	
94°C	30"	
57°C	30"	
68°C	45"	
94°C	30"	25 cycles
62°C	30"	
68°C	45" + 3"	
68°C	7'	
4°C	over night	

[0062] With this RT-PCR protocol a band of 597 bp was amplified from chicken total duodenal RNA. The PCR band was isolated from a 1% agarose gel, cloned into pGEM-T Easy cloning vector and subsequently sequenced. The original peptide is present in the sequence as well as an open reading frame over the whole sequence of 597 bp.

C) Chicken cDNA-library:

[0063] From chicken duodenal polyA⁺ RNA cDNA was made with the Copy Kit (Invitrogen, San Diego) using a modified Gubler-Hoffman procedure. The cDNA was size-selected (0.9-5.5 kb) and cloned into the eukaryotic expression vector pcDNA1.1/Amp (Invitrogen).

[0064] Electroporation into E.coli Top10 was done with a Bio-Rad Gene Pulser II system following the standard protocol. This resulted in a cDNA library of 480'000 individual clones. The library was splitted into 250 pools with 1500-2500 individual clones each. Each pool was amplified in 100 ml LB medium: Bacterial growth was stopped at OD 0.8-1.0 by adding chloramphenicol to a final concentration of 170 µg/ml. Incubation was continued over night in order to increase the DNA amount.

D) Activity screening of the chicken cDNA library:

[0065] 90 of the above pools were tested for activity in a transactivation assay based on the detection of retinoic acid which is produced in eukaryotic cells after β-carotene cleavage. The principle of the activity test is shown in Fig. 2.

[0066] 5 µg of DNA from each pool were transfected with 20 µg of lipofectin (Life Technologies) into a reporter cell line bearing a luciferase reporter plasmid with a RARE (retinoic acid response element) in front of the tk promoter (Herpes simplex thymidine kinase promoter). Transfections were done for 7 h under serum free conditions. After 7 h the transfection mix was removed and RPMI medium with 10% charcoal treated FCS (fetal calf serum) was added. After 20 h of incubation β-carotene (β-carotene 10% CWS, F. Hoffmann-La Roche Ltd.) or a placebo formulation were added to the culture medium to a final β-Carotene concentration of 5 µM. Incubation was continued for 18 h. Then cells were washed with PBS, and luciferase expression was measured after substrate addition with a nitrogen cooled slow scan CCD camera (AstroCam Ltd.) Exposure time usually was 8 min. Analysis was done with the Image Pro Plus 3.0 software package (Media Cybernatic, Maryland). 3 pools were strongly positive, 7 pools showed weaker, but detectable activity.

[0067] One of the positive pools was plated on a square agar plate. 2 filters (nylon membranes, Gene Screen, NEN Research Products, Boston) were processed and screened with the radioactively ([α³²P]dATP, Amersham) labeled 597 bp PCR-fragment. From 9500 colonies screened, 14 were double positive. From 36 colonies picked, 5 showed the same pattern after restriction site analysis. 2 clones were sequenced from the 5' end and the original 51 bp sequence was found. Subsequently the whole cDNA was sequenced and confirmed twice.

[0068] All molecular biological procedures were done according to Sambrook, Fritsch and Maniatis, Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989, if not otherwise mentioned.

[0069] The obtained cDNA sequence is shown in Figure 3 and the amino acid sequence deduced therefrom in Figure 4.

[0070] Figure 4 shows the derived amino acid sequence having 526 residues.

Example 5: Sequence comparison:

[0071] By sequence comparison with the EMBL Genbank a high homology between the known protein RPE65 (Hamel et al., J.Biol.Chem. [1993] p. 15751-15757) and the β,β -carotene 15,15' dioxygenase was found. A homology of 55.5% on the aminoacid level was found. The sequence alignment is shown in Figure 5.

Example 6:**Expression of the cDNA for β,β -carotene 15,15'-dioxygenase in E. coli:**

[0072] With PCR the coding sequence of the β,β -carotene 15,15'-dioxygenase cDNA was amplified and the resulting fragment of 1578 bp was cloned into the EcoRI/BamHI site of the prokaryotic expression vector pQE-12 (Qiagen). The vector contains an in frame hexa-His affinity tag at the C-terminus of the dioxygenase.

[0073] In addition this plasmid contains a regulated promoter with two lacI repressor binding sites.

[0074] The E.coli strain M15pREP4 was transformed with the expression plasmid. For expression 1 l LB medium, containing 100 μ g/ml ampicillin and 25 μ g/ml kanamycin, was inoculated with 30 ml of an overnight culture. Growth was allowed until OD₆₀₀ of 0.6-0.8. At this point the culture was induced with 1 mM IPTG (isopropyl- β -thiogalactoside) and growth continued for another 1.5-2 hours. Bacteria were harvested by centrifugation and the pellet was frozen at -80°C.

[0075] The pellet was thawed by stirring in 20 ml extraction buffer (300 mM NaCl, 50 mM NaH₂PO₄, 20 mM Tris-HCl, 1 mg/ml Tween 40; pH 7.8) including 2.5 mg/ml dodecyl- β -D-maltoside. 1 ml protease inhibitor cocktail (5.9 mM benzamidine-HCl, 10 mM 6-amino-caproic acid, 5 μ M soybean trypsin inhibitor) was added at the same time.

[0076] The bacterial cells were lysed by 4 min. treatment with a Polytron (Kinematica AG, Switzerland) using a PT7 unit following 4 min. sonication with a Branson Sonifier 250.

[0077] The lysate was spun at 12000 x g and the supernatant purified over a Co²⁺-chelate column (Talon Superflow Resin, Clontech, Heidelberg, Germany). The protein was eluted with 15-20 ml of extraction buffer containing 150 mM imidazole.

[0078] The fractions were loaded on a 10% polyacrylamide gel and the protein containing fractions dialysed against 150 mM tricine, 5 mM FeSO₄, 3 mg/ml reduced glutathione, 0.21 mg/ml sodium cholate. The gel is shown in Fig. 6. The samples were then assayed in the dioxygenase activity assay.

Example 7:**Expression of recombinant β,β -carotene 15,15'-dioxygenase in the human duodenal cell line HuTu80:**

[0079] With PCR the coding sequence of the β,β -carotene 15,15'-dioxygenase cDNA was amplified and the resulting fragment of 1578 bp was cloned into the BamHI/XhoI site of the plasmid pSFV₂gen. This vector is part of the Semliki Forest Virus expression system, which works highly efficiently in most mammalian cells.

[0080] The plasmid was used for in vitro synthesis of recombinant RNA, which was subsequently electroporated together with a helper virus into BHK cells (baby hamster kidney cells) for production of a high titer virus stock. With an aliquot of this stock the human duodenal cell line HuTu80 was infected. 16-18 h after infection the cells were harvested and the pellet frozen at -80°C. Either the whole cell pellet, the cytoplasmic fraction or the membrane fraction was used in an activity assay. β,β -carotene 15,15'-dioxygenase activity was found in the whole cell extract and in cytosolic fractions, while in the membrane fraction no activity was detected.

Example 8: **β,β -carotene 15,15'-dioxygenase activity of the recombinant protein expressed in E.coli and in human cells:**

[0081] After expression in E. coli and purification over a metal chelate column, the protein shows cleavage activity with β -carotene as substrate. Retinal was the only product detected by HPLC after incubation with β -carotene. No apocarotenals or other metabolites were found. This could be proved by HPLC analysis as shown in Fig. 7 and 8.

SEQUENCE LISTING

5

<110> F. Hoffmann La Roche AG

10

<120> beta,beta-carotene 15,15'-dioxygenases, nucleic acid
sequences coding therefore and their use

<130>

<140>

15

<141>

<150> 99.103382.0

<151> EP 1999-02-22

20

<160> 10

<170> PADAT Sequenzmodul, Version 1.0

25

30

35

40

45

50

55

<210> 1
 <211> 526
 <212> PRT
 <213> Gallus gallus

<400> 1

10 Met Glu Thr Ile Phe Asn Arg Asn Lys Glu Glu His Pro Glu Pro Ile
 1 5 10 15
 Lys Ala Glu Val Gln Gly Gln Leu Pro Thr Trp Leu Gln Gly Val Leu
 20 25 30
 Leu Arg Asn Gly Pro Gly Met His Thr Ile Gly Asp Thr Lys Tyr Asn
 35 40 45
 His Trp Phe Asp Gly Leu Ala Leu Leu His Ser Phe Thr Phe Lys Asn
 50 55 60
 Gly Glu Val Tyr Tyr Arg Ser Lys Tyr Leu Arg Ser Asp Thr Tyr Asn
 65 70 75 80
 Cys Asn Ile Glu Ala Asn Arg Ile Val Val Ser Glu Phe Gly Thr Met
 85 90 95
 Ala Tyr Pro Asp Pro Cys Lys Asn Ile Phe Ala Lys Ala Phe Ser Tyr
 100 105 110
 Leu Ser His Thr Ile Pro Glu Phe Thr Asp Asn Cys Leu Ile Asn Ile
 115 120 125
 25 Met Lys Thr Gly Asp Asp Tyr Tyr Ala Thr Ser Glu Thr Asn Phe Ile
 130 135 140
 Arg Lys Ile Asp Pro Gln Thr Leu Glu Thr Leu Asp Lys Val Asp Tyr
 145 150 155 160
 Ser Lys Tyr Val Ala Val Asn Leu Ala Thr Ser His Pro His Tyr Asp
 165 170 175
 30 Ser Ala Gly Asn Ile Leu Asn Met Gly Thr Ser Ile Val Asp Lys Gly
 180 185 190
 Arg Thr Lys Tyr Val Leu Phe Lys Ile Pro Ser Ser Val Pro Glu Lys
 195 200 205
 Glu Lys Lys Lys Ser Cys Phe Lys His Leu Glu Val Val Cys Ser Ile
 210 215 220
 35 Pro Ser Arg Ser Leu Leu Gln Pro Ser Tyr Tyr His Ser Phe Gly Ile
 225 230 235 240
 Thr Glu Asn Tyr Ile Val Phe Ile Glu Gln Pro Phe Lys Leu Asp Ile
 245 250 255
 40 Val Lys Leu Ala Thr Ala Tyr Ile Arg Gly Val Asn Trp Ala Ser Cys
 260 265 270
 Leu Ser Phe His Lys Glu Asp Lys Thr Trp Phe His Phe Val Asp Arg
 275 280 285
 Lys Thr Lys Lys Glu Val Ser Thr Lys Phe Tyr Thr Asp Ala Leu Val
 290 295 300
 45 Leu Tyr His His Ile Asn Ala Tyr Glu Glu Asp Gly His Val Val Phe
 305 310 315 320
 Asp Ile Val Ala Tyr Arg Asp Asn Ser Leu Tyr Asp Met Phe Tyr Leu
 325 330 335
 50 Lys Lys Leu Asp Lys Asp Phe Glu Val Asn Asn Lys Leu Thr Ser Ile
 340 345 350
 Pro Thr Cys Lys Arg Phe Val Val Pro Leu Gln Tyr Asp Lys Asp Ala
 355 360 365

EP 1 031 627 A1

	Glu	Val	Gly	Ser	Asn	Leu	Val	Lys	Leu	Pro	Thr	Ser	Ala	Thr	Ala	Val
	370					375						380				
5	Lys	Glu	Lys	Asp	Gly	Ser	Ile	Tyr	Cys	Gln	Pro	Glu	Ile	Leu	Cys	Glu
	385					390					395					400
	Gly	Ile	Glu	Leu	Pro	Arg	Val	Asn	Tyr	Asp	Tyr	Asn	Gly	Lys	Lys	Tyr
					405					410					415	
	Lys	Tyr	Val	Tyr	Ala	Thr	Glu	Val	Gln	Trp	Ser	Pro	Val	Pro	Thr	Lys
				420					425					430		
10	Ile	Ala	Lys	Leu	Asn	Val	Gln	Thr	Lys	Glu	Val	Leu	His	Trp	Gly	Glu
			435				440						445			
	Asp	His	Cys	Trp	Pro	Ser	Glu	Pro	Ile	Phe	Val	Pro	Ser	Pro	Asp	Ala
	450						455					460				
	Arg	Glu	Glu	Asp	Glu	Gly	Val	Val	Leu	Thr	Cys	Val	Val	Val	Ser	Glu
15	465					470					475					480
	Pro	Asn	Lys	Ala	Pro	Phe	Leu	Leu	Ile	Leu	Asp	Ala	Lys	Thr	Phe	Lys
					485					490					495	
	Glu	Leu	Gly	Arg	Ala	Thr	Val	Asn	Val	Glu	Met	His	Leu	Asp	Leu	His
				500					505					510		
20	Gly	Met	Phe	Ile	Pro	Gln	Asn	Asp	Leu	Gly	Ala	Glu	Thr	Glu		
		515						520					525			

25

30

35

40

45

50

55

<210> 2
 <211> 3111
 <212> DNA
 <213> Gallus gallus

<220>
 <223>

<400> 2

```

cggtaccact agtaacggcc gccagtgtgg tggaaatccat ccttctatgt aacaggaaaag   60
agctgttctt agcccagaga ggagggcacc gtacgcctgc aggagcagct gggtagagga   120
cacaggagag cgatggagac aatatttaac agaacaag aagagcatcc agagcccata   180
aaagctgagg tgcaaggcca gttgccctact tggttgcaag gggtaactct ccgaatatggc   240
ccagggatgc acacaatagg ggacactaaa tacaaccact ggtttgatgg cttggctctg   300
ctgcacagct tcacgtttta aaatggtgaa gtttactaca gaagtaagta cctccgaagt   360
gacacatata actgcaatat agaagcaaac cgaatcgtgg tgtctgagtt tggaaacctg   420
gcttatccgg atccatgcaa aaacatatat gccaaaggcat tctcactctt atctcacacc   480
attcctgagt tcacggacaa ctgcctgata aacattatga aaactgggga tgattattat   540
gctaccagty agactaaact catcagaaaa attgatccac agactctgga gacactagat   600
aaggtagact acagcaataa tgtagctgta aacttggcaa cttctcacc accactatgac   660
agtgcctgaa atattctcaa catgggtact tcaattgttg ataaaggag acaaaaatat   720
gttctcttta agatcccttc ctctgtacca gaaaaagaaa agaagaatc ttgttttaaa   780
cacctggaag tagtatgtc catcccttct cgctccctgc tccaaccaag ctactaccac   840
agctttgga tccagaaaaa ttatattgtg ttcataagac agccatttaa actggtatatt   900
gtcaaaactgg caactgccta catccgaggt gtgaactggg ctccctgcct ttcctttcat   960
aaggaggata agacgtggtt tcactttgta gacagaaaga cgaaaaaaga agtatccacc 1020
aagttttaca ctgatgcttt ggtgctttat caccacataa atgcttacga agaagatggc 1080
cacgttgttt ttgatatcgt tgctacaga gacaatagct tgtacgatat gttttactta 1140
aaaaaactgg acaaaagact tgaagtgaac aacaagctta cctccatccc aacctgcaag 1200
cgctttgttg tgcctctgca gtatgacaag gatgcagaag taggttctaa tttagtcaaa 1260
cttccaactt ccgcaactgc tgtaaaaaga aaagatggca gcatctattg tcaacctgaa 1320

```

atattatgtg aagggataga actgcctcgt gtcaactatg actacaatgg caaaaaatac 1380
 aagtatgtct atgcaacaga agtccagtgg agcccgattc ctacaaagat tgcaaaaactg 1440
 5 aatgtccaaa caaaggaagt actgcactgg ggagaagacc actgctggcc ctcagagccc 1500
 atctttgttc ccagccccga tgcaagagaa gaggatgaag gtgttgtttt gacctgtgtt 1560
 10 gtggtgtctg agccaaataa agcacccctc ctactcatct tggatgctaa aacattcaaa 1620
 gaattggggc gagccacagt taacgtagaa atgcatctgg acctgcatgg gatgtttata 1680
 ccacagaatg atttgggggc tgagacggaa taaaacgcta ttgatccgac tacacaaact 1740
 15 gagacaactt totactgaac atgagttaat atccctttta ccattcaaga acaaccatat 1800
 aacgacacaa aatgactatg tataatctct taaataatag atataatcct ttaaggcac 1860
 agcgatgagt ttactacag gtaacgatat gcacaactgg catataacta ttccaaaaga 1920
 20 agaagaacya tcagtgtttt agaagtgcta atgttgtaca taacggcggc agaggggaaca 1980
 ggagagaag gtaacgggaa tatttaatag aatatagatt tctgagcaaa tgaagtgcag 2040
 25 tattttatgt gtgatgcag gcattgagtca cataggctcg cagctcatgt atcttttga 2100
 gatcgtttca agattgcagc ttgtgatgca agttttctcc agccagaaaa cctcatttta 2160
 aaccatctgc tactggtaat tcataccaat gcattttctt ggtgctcgat ttacactata 2220
 30 accaaagtta agtattacat tcagggtgcta caactttcta attacaacc gaacaaaca 2280
 agcaaacagc acttgctttg ctaataaccc catggtgtat ttttcctttt tatgatgaca 2340
 aaaccaagta catatggttt tatgtagcat tcaattatac ttcagtgcta ttccatccta 2400
 35 atgttataag caatttgtat ttaaatcagt ttcccttgag aatctctgac ataacatttt 2460
 gtgtaatgag atgactatgt tgtctaaaga tgaacaggaa tgtatctttt attagtattg 2520
 ttaatttgtt tactaatact atgcatatga atgagagcaa tgtatttcta ggagaactca 2580
 40 gatatacatt caacaatttc tgtaggtgaa aatgcattta ctgatgaaag ttgaatcggt 2640
 aatgagggag aaaactgggt atccatccat ccaactatgt taggtgttca cctggctctgt 2700
 45 atgtgacacc acgctgtttg ggtatctctc acttcccat acctgttctc atggtttctg 2760
 ctactcactg tattttgcag gagagaaaca aaatgaatc actgtcactt actatcgccc 2820
 catcacataa gaacaatggg gctttggtga cttgttcatg attacataag atgtttgcag 2880
 50 cagagcagca atagaacca caccatccac agttcttgct tgctctgtta tgactccctt 2940
 tgctgtcttt atgttttgca tgtatgaaga atacactgcc taattctaat gttaaaaagt 3000

EP 1 031 627 A1

cactggggtc agatctagag ctttaagtaag cagtcctgggg ttttcaaag tttatatgtt 3060

ccataaaatg gaaataaaca cctccataat aaaaaaaaaa aaaaaaaaaa a 3111

<210> 3
<211> 8
<212> PRT
<213> Gallus gallus
<400> 3

Ala Glu Val Gln Gly Gln Leu Pro
1 5

<210> 4
 <211> 506
 <212> PRT
 <213> Gallus gallus

<400> 4

10 Glu Glu His Pro Glu Pro Ile Lys Ala Glu Val Gln Gly Gln Leu Pro
 1 5 10 15
 Thr Trp Leu Gln Gly Val Leu Leu Arg Asn Gly Pro Gly Met His Thr
 20 25 30
 Ile Gly Asp Thr Lys Tyr Asn His Trp Phe Asp Gly Leu Ala Leu Leu
 35 40 45
 15 His Ser Phe Thr Phe Lys Asn Gly Glu Val Tyr Tyr Arg Ser Lys Tyr
 50 55 60
 Leu Arg Ser Asp Thr Tyr Asn Cys Asn Ile Glu Ala Asn Arg Ile Val
 65 70 75 80
 20 Val Ser Glu Phe Gly Thr Met Ala Tyr Pro Asp Pro Cys Lys Asn Ile
 85 90 95
 Phe Ala Lys Ala Phe Ser Tyr Leu Ser His Thr Ile Pro Glu Phe Thr
 100 105 110
 Asp Asn Cys Leu Ile Asn Ile Met Lys Thr Gly Asp Asp Tyr Tyr Ala
 115 120 125
 25 Thr Ser Glu Thr Asn Phe Ile Arg Lys Ile Asp Pro Gln Thr Leu Glu
 130 135 140
 Thr Leu Asp Lys Val Asp Tyr Ser Lys Tyr Val Ala Val Asn Leu Ala
 145 150 155 160
 Thr Ser His Pro His Tyr Asp Ser Ala Gly Asn Ile Leu Asn Met Gly
 165 170 175
 30 Thr Ser Ile Val Asp Lys Gly Arg Thr Lys Tyr Val Leu Phe Lys Ile
 180 185 190
 Pro Ser Ser Val Pro Glu Lys Glu Lys Lys Ser Cys Phe Lys His
 195 200 205
 35 Leu Glu Val Val Cys Ser Ile Pro Ser Arg Ser Leu Leu Gln Pro Ser
 210 215 220
 Tyr Tyr His Ser Phe Gly Ile Thr Glu Asn Tyr Ile Val Phe Ile Glu
 225 230 235 240
 Gln Pro Phe Lys Leu Asp Ile Val Lys Leu Ala Thr Ala Tyr Ile Arg
 245 250 255
 40 Gly Val Asn Trp Ala Ser Cys Leu Ser Phe His Lys Glu Asp Lys Thr
 260 265 270
 Trp Phe His Phe Val Asp Arg Lys Thr Lys Lys Glu Val Ser Thr Lys
 275 280 285
 Phe Tyr Thr Asp Ala Leu Val Leu Tyr His His Ile Asn Ala Tyr Glu
 290 295 300
 45 Glu Asp Gly His Val Val Phe Asp Ile Val Ala Tyr Arg Asp Asn Ser
 305 310 315 320
 Leu Tyr Asp Met Phe Tyr Leu Lys Lys Leu Asp Lys Asp Phe Glu Val
 325 330 335
 Asn Asn Lys Leu Thr Ser Ile Pro Thr Cys Lys Arg Phe Val Val Pro
 340 345 350
 50 Leu Gln Tyr Asp Lys Asp Ala Glu Val Gly Ser Asn Leu Val Lys Leu
 355 360 365

18

[illegible]

<210> 5
 <211> 529
 <212> PRT
 <213> Bos taurus

<400> 5

10 Glu Glu Leu Ser Ser Pro Leu Thr Ala His Val Thr Gly Arg Ile Pro
 1 5 10 15
 Leu Trp Leu Thr Gly Ser Leu Leu Arg Cys Phe Thr Gly Pro Gly Leu
 20 25 30
 Phe Glu Val Gly Ser Glu Pro Phe Tyr His Leu Phe Asp Gly Gln Ala
 35 40 45
 15 Leu Leu His Lys Phe Asp Phe Lys Glu Gly His Val Thr Tyr His Arg
 50 55 60
 Arg Phe Ile Arg Thr Asp Ala Tyr Val Arg Ala Met Thr Glu Lys Arg
 65 70 75 80
 Ile Val Ile Thr Glu Phe Gly Phe Thr Thr Cys Ala Phe Pro Asp Pro
 85 90 95
 20 Cys Lys Asn Ile Phe Ser Arg Phe Phe Ser Tyr Phe Arg Gly Val Glu
 100 105 110
 Val Thr Asp Asn Ala Leu Val Asn Val Tyr Pro Val Gly Glu Asp Tyr
 115 120 125
 25 Tyr Ala Cys Thr Glu Thr Asn Phe Ile Thr Lys Ile Asn Pro Glu Thr
 130 135 140
 Leu Glu Thr Ile Phe Thr Lys Gln Val Asp Leu Cys Asn Tyr Val Ser
 145 150 155 160
 Val Asn Gly Ala Thr Ala His Pro His Ile Glu Asn Asp Gly Thr Val
 165 170 175
 30 Tyr Asn Ile Gly Asn Cys Phe Gly Lys Asn Phe Ser Ile Ala Tyr Asn
 180 185 190
 Ile Val Lys Ile Pro Pro Leu Gln Ala Asp Lys Glu Asp Pro Ile Ser
 195 200 205
 35 Lys Phe Thr Ser Glu Ile Val Val Gln Phe Pro Cys Ser Asp Arg Phe
 210 215 220
 Lys Pro Ser Tyr Val His Ser Phe Gly Leu Thr Pro Asn Tyr Ile Val
 225 230 235 240
 Phe Val Glu Thr Pro Val Lys Ile Asn Leu Phe Lys Phe Leu Ser Ser
 245 250 255
 40 Trp Ser Leu Trp Gly Ala Asn Tyr Met Asp Cys Phe Glu Ser Phe Thr
 260 265 270
 Asn Glu Thr Met Gly Val Trp Leu His Ile Ala Asp Lys Lys Arg Lys
 275 280 285
 Lys Tyr Leu Asn Asn Lys Tyr Arg Thr Ser Pro Phe Asn Leu Phe His
 290 295 300
 45 His Ile Asn Thr Tyr Glu Asp Asn Gly Phe Leu Ile Val Asp Leu Cys
 305 310 315 320
 Cys Trp Lys Gly Phe Glu Phe Val Tyr Asn Tyr Phe Thr Leu Tyr Leu
 325 330 335
 Ala Asn Leu Arg Glu Asn Trp Glu Glu Val Lys Lys Asn Ala Arg Lys
 340 345 350
 50 Ala Pro Gln Pro Glu Val Arg Arg Tyr Val Leu Pro Leu Asn Ile Asp
 355 360 365

EP 1 031 627 A1

5 Lys Ala Asp Thr Gly Lys Asn Leu Val Thr Leu Pro Asn Thr Thr Ala
 370 375 380
 Thr Ala Ile Leu Cys Ser Asp Glu Phe Thr Thr Ile Trp Leu Glu Pro
 385 390 395 400
 Glu Val Leu Phe Ser Gly Pro Arg Gln Ala Phe Glu Phe Pro Gln Ile
 405 410 415
 Asn Tyr Gln Lys Tyr Cys Gly Lys Pro Tyr Thr Tyr Ala Tyr Gly Leu
 420 425 430
 10 Gly Leu Asn His Phe Val Pro Asp Arg Leu Cys Lys Leu Asn Val Lys
 435 440 445
 Thr Lys Glu Thr Trp Phe Thr Val Trp Gln Glu Pro Asp Ser Tyr Pro
 450 455 460
 15 Ser Glu Pro Ile Phe Val Ser His Pro Asp Ala Leu Glu Glu Asp Asp
 465 470 475 480
 Gly Val Val Leu Ser Val Val Val Ser Pro Gly Ala Gly Gln Lys Pro
 485 490 495
 Ala Tyr Leu Leu Ile Leu Asn Ala Lys Asp Leu Ser Glu Val Ala Arg
 500 505 510
 20 Ala Glu Phe Thr Val Glu Ile Asn Ile Pro Val Thr Phe His Gly Leu
 515 520 525
 Phe

25

30

35

40

45

50

55

<210> 6
 <211> 18
 <212> PRT
 <213> Gallus gallus
 <400> 6

10 Asn Lys Glu Glu His Pro Glu Pro Ile Lys Ala Glu Val Gln Gly Gln
 1 5 10 15
 Leu Pro

<210> 7
 <211> 18
 <212> PRT
 <213> Gallus gallus
 <400> 7

20 Asn Lys Glu Glu His Pro Glu Pro Ile Lys Ala Glu Val Gln Gly Gln
 1 5 10 15
 Leu Pro

<210> 8
 <211> 20
 <212> DNA
 <213> artificial sequence

<220>
 <221> modified_base
 <222> 18
 <223> a is Inosine; primer

<400> 8

aacaargarg ascayccaga

20

5 <210> 9
 <211> 21
 <212> DNA
 <213> artificial sequence

 <220>
 10 <221> modified_base
 <222> 7, 13
 <223> a is Inosine; primer

 <400> 9

15 sagctgaccc tgaacytcs g

21

20 <210> 10
 <211> 25
 <212> DNA
 <213> artificial sequence

 <220>
 25 <223> primer

 <400> 10

30 tctgaattcc ggagcccata aaagc

25

35 Claims

1. Protein having β , β -carotene 15,15'-dioxygenase activity comprising an amino acid sequence which is identical or homologous to sequence ID no. 1 whereby the degree of homology to sequence ID no. 1 is at least 60%.
- 40 2. Protein according to claim 1 wherein the degree of homology is at least 70%.
3. Protein according to claim 1 wherein the degree of homology is at least 80%.
4. Protein according to claim 1 wherein the degree of homology is at least 90%.
- 45 5. Protein according to any one of claims 1 to 4 wherein the amino acid sequence is derived from chicken.
6. Nucleic acid sequence coding for a protein according to any one of claims 1 to 5.
- 50 7. Nucleic acid sequence according to claim 6 which comprises at least a part of the sequence of sequence ID no. 2.
8. Nucleic acid sequence according to claim 7 wherein the oligonucleotide has a length of at least 20 bases.
9. Nucleic acid sequence according to any one of claims 6 to 8 wherein the nucleic acid is deoxyribonucleic acid.
- 55 10. Nucleic acid sequence according to any one of claims 6 to 8 wherein the nucleic acid is an antisense ribonucleic acid.

11. Primer for the specific amplification of a gene coding for a protein having β,β -carotene 15,15'-dioxygenase activity which comprises a nucleic acid sequence according to any one of claims 6 to 9.

12. Probe for the detection of a gene coding for a protein having β,β -carotene 15,15'-dioxygenase activity which comprises a nucleic acid sequence according to any one of claims 6 to 9.

13. Testkit for the amplification and/or detection of a gene or a part thereof coding for β,β -carotene 15,15'-dioxygenase comprising at least one primer according to claim 11 and/or at least one probe according to claim 12.

14. Antibody characterized in that said antibody specifically reacts with a protein according to any one of claims 1 to 5.

15. Immunoassay for the detection and/or quantification of β,β -carotene 15,15'-dioxygenase which comprises at least one antibody according to claim 14.

16. Process for the production of vitamin A wherein β -carotene is enzymatically cleaved by a protein according to any one of claims 1 to 5.

17. Method for the introduction of the β,β -carotene 15,15'-dioxygenase cDNA into a host cell wherein a cDNA coding for a protein according to any one of claims 1 to 5 is inserted into a vector suitable for the host cell and said vector is introduced into the host cell.

18. Method according to claim 17 wherein the host cell is a plant cell.

19. Method according to claim 17 wherein the host cell is a prokaryotic cell.

20. Method according to claim 17 wherein the host cell is a yeast cell or another fungus.

21. Method according to claim 17 wherein the host cell is an alga.


22. Method according to claim 17 wherein the host cell is a mammalian cell.

23. Method according to claim 22 wherein the mammalian cell is a human cell.

24. Host cell obtainable by a method according to any one of claims 17 to 23.

25. Host cell according to claim 24 which comprises a β,β -carotene 15,15'-dioxygenase cDNA obtained from another species.

Figure 1






Figure 2

Figure 3
No. 2

Seq. ID

```

1   CGGATCCACT AGTAACGGCC GCCAGTGTGG TGAATCCAT
CCTTCTATGT

51  AACAGGAAAG AGCTGTTCTT AGCCCAGAGA GGAGGGCACC
GTACGCCTGC

101 AGGAGCAGCT GGGTAGAGGA CACAGGAGAG CGATGGAGAC
AATATTTAAC

151 AGAAACAAAG AAGAGCATCC AGAGCCCATA AAAGCTGAGG
TGCAAGGTCA

201 GTTGCCCACT TGGTTGCAAG GGGTACTTCT CCGAAATGGC
CCAGGGATGC

251 ACACAATAGG GGACACTAAA TACAACCACT GGTTTGATGG
CTTGGCTCTG

301 CTGCACAGCT TCACGTTTAA AAATGGTGAA GTTTACTACA
GAAGTAAGTA

351 CCTCCGAAGT GACACATACA ACTGCAATAT AGAAGCAAAC
CGAATCGTGG

401 TGTCTGAGTT TGGAACCATG GCTTATCCGG ATCCATGCAA
AAACATATTT

451 GCCAAGGCAT TCTCATACTT ATCTCACACC ATTCTGAGT
TCACGGACAA

501 CTGCCTGATC AACATTATGA AACTGGGGA TGATTATTAT
GCTACCAGTG

551 AGACTAACTT CATCAGAAAA ATTGATCCAC AGACTCTGGA
GACACTAGAT

601 AAGGTAGACT ACAGCAAATA TGTAGCTGTA AACTTGCAA
CTTCTCACCC

651 ACACTATGAC AGTGCTGGAA ATATTCTCAA CATGGGTACT
TCAATTGTTG

701 ATAAAGGGAG AACAAAATAT GTTCTCTTTA AGATCCCTTC
CTCTGTACCA

751 GAAAAAGAAA AGAAGAAATC TTGTTTAAAA CACCTGGAAG
TAGTATGCTC

801 CATCCCTTCT CGCTCCCTGC TCCAACCAAG CTACTACCAC
AGCTTTGGAA

851 TCACAGAAAA TTATATTGTG TTCATAGAGC AGCCATTTAA
ACTGGATATT

```

901 GTCAAACTGG CAACTGCCTA CATCCGAGGT GTGAACTGGG
 CTTCTGCCT
 951 TTCCTTTCAT AAGGAGGATA AGACGTGGTT TCACTTTGTA
 GACAGAAAGA
 1001 CGAAAAAAGA AGTATCCACC AAGTTTACATA CTGATGCTTT
 GGTGCTTTAT
 1051 CACCACATAA ATGCTTACGA AGAAGATGGC CACGTTGTTT
 TTGATATCGT
 1101 TGCCTACAGA GACAATAGCT TGTACGATAT GTTTTACTTA
 AAAAACTGG
 1151 ACAAGACTT TGAAGTGAAC AACAGCTTA CCTCCATCCC
 AACCTGCAAG
 1201 CGCTTTGTTG TGCCTCTGCA GTATGACAAG GATGCAGAAG
 TAGGTTCTAA
 1251 TTTAGTCAAA CTTCCAACCT CCGCAACTGC TGTAAAAGAA
 AAAGATGGCA
 1301 GCATCTATTG TCAACCTGAA ATATTATGTG AAGGGATAGA
 ACTGCCTCGT
 1351 GTCAACTATG ACTACAATGG CAAAAAATAC AAGTATGTCT
 ATGCAACAGA
 1401 AGTCCAGTGG AGCCCAGTTC CTACAAAGAT TGCAAACTG
 AATGTCCAAA
 1451 CAAAGGAAGT ACTGCACTGG GGAGAAGACC ACTGCTGGCC
 CTCAGAGCCC
 1501 ATCTTTGTTC CCAGCCCCGA TGCAAGAGAA GAGGATGAAG
 GTGTTGTTTT
 1551 GACCTGTGTT GTGGTGTCTG AGCCAAATAA AGCACCCCTC
 CTACTCATCT
 1601 TGGATGCTAA AACATTCAAA GAATTGGGCC GAGCCACAGT
 TAACGTAGAA
 1651 ATGCATCTGG ACCTGCATGG GATGTTTATA CCACAGAATG
 ATTTGGGGGC
 1701 TGAGACGGAA TAAAACGCTA TTGATCCGAC TACACAACT
 GAGACAACTT
 1751 TCTACTGAAC ATGAGTTAAT ATCCCTTTTA CCATTCAAGA
 ACAACCATAT
 1801 AACGACACAA AATGACTATG TATAATCTCT TAAATAATAG
 ATATAATCCT
 1851 TTTAAGGCAC AGCGATGAGT TTTACTACAG GTAACGATAT
 GCACAACTGG

1901 CATATACTA TTCCAAAAGA AGAAGAACGA TCAGTGTTTT
 AGAAGTGCTA
 1951 ATGTTGTACA TAACGGCGGC AGAGGGAACA GGAGAGAAAG
 GTAACGGGAA
 2001 TATTTAATAG AATATAGATT TCTGAGCAAA TGAAGTGCAG
 TATTTATGGT
 2051 GTGATGCATG GCATGAGTCA CATAGGTCTG CAGCTCATGT
 ATCTTTTAGA
 2101 GATCGTTTCA AGATTGCAGC TTGTGATGCA AGTTTTCTCC
 AGCCAGAAAA
 2151 CCTCATTTTA AACCATCTGC TACTGGTAAT TCATACCAAT
 GCATTTTCTT
 2201 GGTGCTCGAT TTACACTATA ACCAAAGTTA AGTATTACAT
 TCAGGTGCTA
 2251 CAACTTTCTA ATTTACAACC GAAACAAACA AGCAAACAGC
 ACTTGCTTTG
 2301 CTAATAACCC CATGGTGTAT TTTTCCTTTT TATGATGACA
 AAACCAAGTA
 2351 CATATGGTTT TATGTAGCAT TCAATTATAC TTCAGTGCTA
 TTCCATCCTA
 2401 ATGTTATAAG CAATTTGTAT TTAAATCAGT TTTTCCTGAG
 AATATCTGAC
 2451 ATAACATTTT GTGTAATGAG ATGACTATGT TGTCTAAAGA
 TGAACAGGAA
 2501 TGTATCTTTT ATTAGTATTG TTAATTGTGT TACTAATACT
 ATGCATATGA
 2551 ATGAGAGCAA TGTATTTCTA GGAGAACTCA GATATACATT
 CAACAATTC
 2601 TGTAGGTGAA AATGCATTTA CTGATGAAAG TTGAATCGTT
 AATGAGGGAG
 2651 AAAACTGGGT ATCCATCCAT CCAACTATGT TAGGTGTTCA
 CCTGGTCTGT
 2701 ATGTGACACC ACGCTGTTTG GGTATCTCTC ACTTTCACAT
 ACCTGTTCTC
 2751 ATGGTTTCTG CTACTCACTG TATTTTGCAG GAGAGAAACA
 AAATGAAATC
 2801 ACTGTCACCT ACTATCGCCC CATCACATAA GAACAATGGG
 GCTTTGGTGA

2851 CTTGTTTCATG ATTACATAAG ATGTTTGCAG CAGAGCAGCA
ATAGAACCAA

2901 CACCATCCAC AGTTCTTGCT TGCTCTGTTA TGA CTCCCTT
TGCTGTCTTT

2951 ATGGTTTGCA TGTATGAAGA ATACACTGCC TAATTCTAAT
GTTAAAAAGT

3001 CACTGGGGTC AGATCTAGAG CTTAAGTAAG CAGTCTGGGG
TTTTCAAATG

3051 TTTATATGTT CCATAAAATG GAAATAAACA CCTCCATAAT
AAAAAAAAAA

3101 AAAAAAAAAA A

Figure 4
No. 1

Seq. ID

1 METIFNRNKE EHPEPIKAEV QGQLPTWLQG VLLRNGPGMH
TIGDTKYNHV

51 FDGLALLHSF TFKNGEVYR SKYLRSDTYN CNIEANRIVV
SEFGTMAYPD

101 PCKNIFAKAF SYLSHTIPEF TDNCLINIMK TGDDYYATSE
TNFIRKIDPQ

151 TLETLDKVDY SKYVAVNLAT SHPHYDSAGN ILNMGTSIVD
KGRTKYVLFK

201 IPSSVPEKEK KKSCFKHLEV VCSIPSRSLI QPSYYHSFGI
TENYIVFIEQ

251 PFKLDIVKLA TAYIRGVNWA SCLSFHKEDK TWPHFVDRKT
KKEVSTKFYT

301 DALVLYHHIN AYEEDGHVVF DIVAYRDNLS YDMFYLLKLD
KDFEVNNKLT

351 SIPTCKRFVV PLQYDKDAEV GSNLVKLPTS ATAVKEKDGS
IYCQPEILCE

401 GIELPRVNYD YNGKKYKYVY ATEVQWSPVP TKIAKLVNQT
KEVLHWGEDH

451 CWPSEPIFVP SPDAREEDEG VVLTCVVVSE PNKAPFLIL
DAKTFKELGR

501 ATVNVMHLD LHGMFIPQND LGAETE

Figure 5

Seq ID No. 4 and Seq ID No. 5

```

57 10 EEHPEPIKAÆVQGQLPTWLQGVLLR..NGPGMHTIGDTKYNHWF DGLALL
    ||  | : | | | . : | | | | | | | | : | : | | | | | |
69 20 EELSSPLTAHV TGRIPLWLTGSLLRCTGPGLFEVGSEPFYHLFDGQALL
    | | | | | | | | : : | | | | | | | | | | | | | |
105 58 HSFTFKNGEVY YRSKYLRSDTYNCNIEANRIVVSEFG..TMAYPD PCKNI
    | | | | | | | | : : | | | | | | | | | | | | | |
119 70 HKFDFKEGHV TYHRRFIRTDAYVRAMTEKRIVITEFGFTTCAFPDPCKNI
    | | | | | | | | : : | | | | | | | | | | | | | |
155 106 FAKAFSYLSHTIPEFTDNCLINIMKTGDDYATSETNFIRKIDPQTLETL
    | . : | | | | | | | | : : | | | | | | | | | | : | | | :
167 120 FSRFFSYFRGV..EVTDNALVNVYPVGEDYACTETNFITKINPETLETI
    | | | | | | | | : : | | | | | | | | | | | | | |
203 156 ..DKVDYSKYVAVNLATSHPHYDSAGNILNMGTSIVDKGR TKYVLFKIPS
    . | | | | | | | | : : | | | | | | | | : | | |
217 168 FTKQVDLCNYVSVNGATAHPHIENDGTVYNIGNCFGKNFSIAYNIVKIPP
    | | | | | | | | : : | | | | | | | | : | | |
253 204 SVPEKEKKKSCFKHLEVVC SIPSRLLQPSYYHSFGITENYIVFIEQPFK
    : | | | | | | | | : : | | | | | | | | : | | |
266 218 LQADKEDPISKFTS.EIVVQFPCSDRFKPSYVHSFGLTPNYIVFVETPVK
    | | | | | | | | : : | | | | | | | | : | | |
300 254 LDIVKLATAY.IRGVNWASCL.SFHKEDK.TWFHFVDRKTKKEVSTKFYT
    : : | | : : | | : | | | | | | | : | | | | . : |
316 267 INLFKFLSSWSLWGANYMDCFESFTNETMGVWLHIADKKRKKYLNNKYRT
    | | | | | | | | : : | | | | | | | | : | | |
344 301 DALVLYHHINAYEEDGHVVF DIVAYRDN SL...YDMFYLK KLDKDFE...
    | : | | | | | | : : | : : : | | | | | | | | . . . |
366 317 SPFNLFHHINTYEDNGFLIVDLCCWKGF EFVYNYFTLYLANLRENWEEVK
    | | | | | | | | : : | | | | | | | | : | | |
391 345 VNNKLTSIPTCKRFV VPLQYDKDAEVGSNLVKLP.TSATAV..KEKD GSI
    | : | | | | | | : : | | | | | | | | : | | |
415 367 KNARKAPQPEVRRYV LPLNIDK.ADTGKNLVTL PNTTATAILCSDEFTTI
    | : | | | | | | : : | | | | | | | | : | | |
436 392 YCQPEILCEG....IELPRVNYD.YNGKKYKYVYATEVQWSPVPTKIAKL
    : : | | : | | | | | : : | | | | | | | | : | | |
464 416 WLEPEVLFSGPRQAF EFPQINYQKYCGKPYTYAYGLGLNHF.VPDR LCKL
    | | | | | | | | : : | | | | | | | | : | | |

```

484 437 NVQTKVELH..WGEDHCWPSEPIFVPSPDAREEDEGVVLTVCVVVSEPNKA
 465 ||.||| | | : || || || | || | || : || | . ||
 514 NVKTKETWFTVWQEPDSYPSEPIFVSHPDAL EEDDGVVLSVVVSPGAGQK
 485 P.FLLILDAKTFKELGRA..TVNVEMHLDLHGME 515
 515 | : || || . || | . || | : . . || : |
 PAYLLILNAKDLSEVARAEFTVEINIPVTFHGLF 548

BEST AVAILABLE COPY




Fig. 6 shows a 10% polyacrylamide gel with E.coli expressed β,β -carotene 15,15'-dioxygenase after affinity tag purification; lane 1 and lane 2: 2 fractions from the Co^{2+} -chelate column showing the main band at 60 kD; lane 3: low range molecular weight marker (Bio Rad).




Fig. 7 shows an HPLC profile of the reaction mixture at the end of an activity assay for the β,β -carotene 15,15'-dioxygenase following the procedure in example 1. The first peak in the chromatogram represents the internal standard, while the second peak corresponds to retinal as the only product formed during the central cleavage with β -carotene as substrate.




Fig. 8 confirms that the product peak in Fig. 7 is indeed retinal. A sample which was positive in the activity assay (green chromatogram) was spiked with retinal and analysed in second HPLC run (red chromatogram). The chromatograms of the two runs were then overlaid.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 00 10 2289

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
D, A	<p>DEVERY J ET AL: "Beta-carotene-15,15'-dioxygenase (EC 1.13.11.21) isolation reaction method and an improved assay procedure." BRITISH JOURNAL OF NUTRITION., vol. 72, no. 3, September 1994 (1994-09), pages 397-414, XP000914668 CAMBRIDGE., GB * abstract *</p> <p>-----</p> <p>A WO 93 23538 A (LUDWIG INST CANCER RES ;BAVIK CLAES OLOF (SE); ERIKSSON ULF (SE);) 25 November 1993 (1993-11-25) * page 21 - page 24 *</p> <p>-----</p>	<p>1</p> <p>1</p>	<p>C12N15/53 C12N9/02 C12N1/21 C12N5/10 C12P23/00 C07K16/40 C12Q1/68 G01N33/573 //(C12N1/21, C12R1:19)</p>
			<p>TECHNICAL FIELDS SEARCHED (Int.Cl.7)</p> <p>C12N C12P C07K G01N C12Q</p>
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 13 June 2000	Examiner Lejeune, R
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p>		<p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>..... & : member of the same patent family, corresponding document</p>	

EPO FORM 1503/03-02 (P4/C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 10 2289

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

13-06-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9323538 A	25-11-1993	AU 4375493 A	13-12-1993
		US 5573939 A	12-11-1996
		US 5679772 A	21-10-1997

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

THIS PAGE BLANK (USPTO)